Carbylan Therapeutics (CBYL) Misses Q2 EPS by 16c

Carbylan Therapeutics (NASDAQ: CBYL) reported Q2 EPS of ($0.37), $0.16 worse than the analyst estimate of ($0.21).

For earnings history and earnings-related data on Carbylan Therapeutics (CBYL) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• JD.com (JD) Reiterated at Buy by Benchmark Amid Earnings Recovery
• Boost Run, Inc. (BRUN) Reports Q2 Revenue of $31.1M